R1 Therapeutics

R1 Therapeutics is a private, preclinical-stage biotech company targeting kidney disease with novel small molecule therapeutics. Founded in 2020 and headquartered in San Diego, the company is in the early stages of research and development, positioning itself to tackle a large and growing market with high unmet need. As a pre-revenue entity, its success will depend on advancing its pipeline through preclinical validation and into clinical trials, likely supported by venture capital funding.

Small molecule drug discovery for renal diseases; specific platform details not disclosed.

The nephrology therapeutic landscape is becoming increasingly competitive, with large pharma companies and numerous biotechs pursuing novel mechanisms for CKD, DKD, and rare kidney diseases. R1 will need to differentiate through a novel mechanism of action or superior efficacy/safety.